Crossmark

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD

Published Online: 2021-09-29

Published Print: 2022-01

Authors

Arnold, Danielle E.

Nofal, Rofida

Wakefield, Connor

Lehmberg, Kai

Wustrau, Katharina

Albert, Michael H.

Morris, Emma C.

Heimall, Jennifer R.

Bunin, Nancy J.

Kumar, Ashish

Jordan, Michael B.

Cole, Theresa

Choo, Sharon

Brettig, Tim

Speckmann, Carsten

Ehl, Stephan

Salamonowicz, Malgorzata

Wahlstrom, Justin

Rao, Kanchan

Booth, Claire

Worth, Austen

Marsh, Rebecca A. https://orcid.org/0000-0002-9645-0617
License Information

Text and Data Mining valid from 2021-09-29

Version of Record valid from 2021-09-29
More Information

Article History

Received: 18 January 2021

Accepted: 16 July 2021

First Online: 29 September 2021

Declarations

:

: The study was approved by the Cincinnati Children’s Hospital institutional review board.

: Not applicable.

: Not applicable.

: JW is employed by AbbVie. AK and MBJ have done ad hoc consultancy for Swedish Orphan Biovitrum. CB has done ad hoc consultancy for Novimmune and Swedish Orphan Biovitrum. The remaining authors have no relevant conflicts of interest to disclose.

Document is current